FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Библиотека стаков

Lean Body Recomp

Fat Lossbeginner
44
Share
Пептиды

2

Среднедневная дозировка мкг

500

Уровень

beginner

Добавлено

May 16, 2026

Обзор

The Lean Body Recomp is a streamlined, beginner-friendly peptide stack engineered for efficient fat loss while preserving lean muscle tissue. By combining AOD-9604, a modified fragment of human growth hormone specifically targeting lipolysis, with Ipamorelin, a selective growth hormone secretagogue, this protocol attacks body fat through dual metabolic pathways without the side effects associated with full-length GH administration. AOD-9604 at 300mcg daily is derived from the fat-burning region of the growth hormone molecule (amino acids 177-191) and has been shown to stimulate lipolysis and inhibit lipogenesis without affecting blood sugar levels or promoting tissue growth. Unlike full-length HGH, it does not cause insulin resistance, water retention, or joint pain, making it an ideal targeted fat-loss agent. Ipamorelin at 200mcg daily complements this by stimulating clean, physiological GH pulses that enhance metabolic rate, support muscle protein synthesis, and improve sleep quality, all of which contribute to favorable body recomposition. The synergy in this stack is elegant: AOD-9604 directly mobilizes stored fat for oxidation while Ipamorelin maintains the anabolic and metabolic environment needed to prevent muscle catabolism during a caloric deficit. The result is a shift in body composition rather than simple weight loss. For optimal results, administer AOD-9604 in the morning on an empty stomach, at least 30 minutes before eating, to maximize its lipolytic window. Ipamorelin is best taken before bed on an empty stomach (no food for 2 hours prior) to amplify nocturnal GH release. Avoid high-fat meals within an hour of either injection. This stack is suited for beginners looking to reduce body fat percentage while maintaining or slowly building lean mass. It works best when paired with a moderate caloric deficit (300-500 calories below maintenance), regular resistance training, and adequate protein intake. Research on AOD-9604 has demonstrated fat reduction without appetite changes, while Ipamorelin studies confirm selective GH release without cortisol or prolactin elevation. Typical cycles run 8-12 weeks.

Протокол дозирования

300 mcg

на дозу

200 mcg

на дозу

Цели и доказательства

Уровень доказательств:community

Comments

Sign in to join the discussion

Уведомление: Этот стак представлен сообществом и предназначен для исследовательских целей только. Peptide Contacts не проверяет безопасность или эффективность представленных стаков. Всегда проконсультируйтесь с квалифицированным медицинским специалистом перед использованием любого протокола пептидов.